Efficacy and safety of diacerein monotherapy in adults with obesity: A randomized, double‐blind, placebo‐controlled trial
Diabetes, Obesity and Metabolism · 2024
DOI: 10.1111/dom.15881 ↗Kurz gefasst
Randomisierte kontrollierte Studie in der Zeitschrift Diabetes, Obesity and Metabolism, 2024. Verfasst von Yingying Xiang und 10 weiteren Autor:innen. Beteiligte Einrichtung: Department of Endocrinology, Jiangsu Province Hospital of Chinese Medicine, The Affiliated Hospital of Nanjing University of Chinese Medicine, Nanjin…. Hauptthemen laut MEDLINE: Obesity, Anthraquinones, Weight Loss. Die Arbeit nennt 39 Literaturangaben. Gefördert von: The Open Projects of the Discipline of Chinese Medicine of Nanjing University of Chinese Medicine Supported by the Subject of Academic Priority Discipline of J…, Postgraduate Research and Practice Innovation Program of Jiangsu Province.
Abstract (Originalsprache)
Aim
To assess the efficacy and safety of diacerein monotherapy in adults with obesity.
Methods
Forty‐two adults with obesity participated in the study and were randomly assigned to receive diacerein or placebo in addition to lifestyle modification for 14 weeks, in a double‐blinded fashion. Differences in changes in body weight, body composition, metabolic variables, fatty liver‐related indicators, cardiovascular system variables, lifestyle score and metabolic factors were compared.
Results
Post‐treatment weight loss percentage from baseline was −6.56% (−8.71%, −4.41%) in the diacerein group and −0.59% (−2.74%, 1.56%) in the placebo group. Compared with the placebo group, the diacerein group showed significant improvements in body composition, metabolic variables and indicators related to fatty liver. In addition, after 14 weeks of treatment, diacerein led to a significant reduction in serum visfatin concentration versus the placebo group. The reductions in total body fat mass and visceral fat area mediated the weight loss induced by diacerein. No significant differences were found between the groups in the number of adverse events and safety variables.
Conclusions
For adults with obesity, diacerein led to a clinically meaningful weight loss and provided multiple metabolic benefits with acceptable safety. These results support that diacerein is a promising candidate medicine to be developed for obesity management.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Endocrinology, Jiangsu Province Hospital of Chinese Medicine, The Affiliated Hospital of Nanjing University of Chinese Medicine, Nanjing, China.
- Key Laboratory for Metabolic Diseases in Chinese Medicine, Nanjing University of Chinese Medicine, Nanjing, China.
ORCID-Profile: Yingying Xiang, Wenbin Shang
Förderung
- The Open Projects of the Discipline of Chinese Medicine of Nanjing University of Chinese Medicine Supported by the Subject of Academic Priority Discipline of J…
- Postgraduate Research and Practice Innovation Program of Jiangsu Province
Zitieren
APA
Xiang, Y., Shen, L., Xue, Y., Wang, Z., Zhou, R., Cao, Y., Zhu, Z., Xu, P., Yu, X., Fang, P., & Shang, W. (2024). Efficacy and safety of diacerein monotherapy in adults with obesity: A randomized, double‐blind, placebo‐controlled trial. Diabetes, Obesity and Metabolism. https://doi.org/10.1111/dom.15881
Vancouver
Xiang Y, Shen L, Xue Y, Wang Z, Zhou R, Cao Y, et al. Efficacy and safety of diacerein monotherapy in adults with obesity: A randomized, double‐blind, placebo‐controlled trial. Diabetes, Obesity and Metabolism. 2024. doi:10.1111/dom.15881
BibTeX
@article{Xiang2024,
author = {Xiang, Yingying and Shen, Lixuan and Xue, Yingying and Wang, Ziwei and Zhou, Ruonan and Cao, Yue and Zhu, Ziwei and Xu, Pingyuan and Yu, Xizhong and Fang, Penghua and Shang, Wenbin},
title = {Efficacy and safety of diacerein monotherapy in adults with obesity: A randomized, double‐blind, placebo‐controlled trial},
journal = {Diabetes, Obesity and Metabolism},
year = {2024},
doi = {10.1111/dom.15881}
}
EUVIMED